• Ascorbic Acid In Type 2 Diabetes

    From ironjustice@21:1/5 to All on Sat Dec 22 14:40:41 2018
    Ascorbic acid supplementation improves postprandial glycaemic control and blood pressure in individuals with type 2 diabetes: Findings of a randomized cross-over trial.
    Mason SA1, Rasmussen B2,3, van Loon LJC4, Salmon J1, Wadley GD1.
    Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13571.
    The primary aim of this study was to investigate whether ascorbic acid (AA) supplementation improves postprandial glucose responses under free-living conditions in individuals with type 2 diabetes. A secondary aim was to investigate the effect of AA
    supplementation on blood pressure.

    A total of 31 individuals with type 2 diabetes (26 males and 5 females; aged 61.8 ± 6.8 years; duration of diabetes, 5.6 ± 4.6 years; HbA1c, 7.6% ± 0.7% [mean ± SD]) were enrolled in a randomized cross-over study involving 4 months
    of supplementation with oral AA (2 × 500 mg/d) or placebo. Participants wore continuous glucose monitors for 48 hours and consumed standardized meals pre- and post-supplementation. Measurements included postprandial glucose incremental areas under
    the curve (iAUC), duration of day in hyper- and hypo-glycaemia status, average 24-hour and daily postprandial glucose concentrations, HbA1c, insulin, blood pressure (BP) and oxidative stress (F2 -isoprostanes).

    Following AA supplementation, significant decreases were observed in daily postprandial glucose iAUC (-36%), in duration of day with hyperglycaemia (-2.8 h/d) and postprandial hyperglycaemia (-1.7 h/d), in average 24-hour glucose (-0.8 mmol/L) and daily
    postprandial glucose (-1.1 mmol/L) concentrations, in systolic (-7 mm Hg) and diastolic (-5 mm Hg) blood pressures and in a specific fraction of free plasma F2 -isoprostanes (-47 pg/mL) as compared to placebo.

    Individuals with type 2 diabetes experienced improved postprandial and 24-hour glycaemia and decreased BP after 4 months of AA supplementation as compared to placebo. These findings offer evidence for the proposed use of AA as an adjunct therapy to
    improve glycaemic and BP control in individuals with type 2 diabetes.

    © 2018 John Wiley & Sons Ltd.

    antidiabetic drug; clinical trial; continuous glucose monitoring (CGM); glycaemic control; randomised trial; type 2 diabetes

    PMID: 30394006 DOI: 10.1111/dom.13571

    Who loves ya.

    Jesus Was A Vegetarian!

    Man Is A Herbivore!


    --- SoupGate-Win32 v1.05
    * Origin: fsxNet Usenet Gateway (21:1/5)